# Borrow a Word People Already Believe — Notes on Medsider on Building Trust in an Untouched Aisle Source: Realpha Blog (blog.getrealpha.com) Original article and charts: https://blog.getrealpha.com/en/blog/medsider-2026-11-16-how-to-build-trust-in-a-new-category-interview-wit/ > Listening notes on the 16 November 2026 episode of Medsider, where Scott Nelson interviews Wizard Wellness founder and CEO Lorne Lucree: he carried the vocabulary consumers already bought into from skincare and gut health straight into allergy care, skipping the cost of educating from scratch. The piece takes apart the evidence behind that move, the conditions under which it breaks, and why retail access and supply chain may be the real source of his lead. Educational discussion of method, not investment advice; no stock recommendations or price targets. Published: 2026-11-18 Locale: en Tags: Medsider, brand building, consumer startups, category education, startup fundraising ![A long drugstore aisle receding into the depth of the frame, the shelves nearest the camera packed with glossy skincare bottles lit hard by the ceiling strips, the far end where the allergy products sit falling into cooler dimmer light, a single shopper standing there with their back to the camera looking down at a small carton](/covers/medsider-2026-11-16-how-to-build-trust-in-a-new-category-interview-wit-cover.png) > Illustration by analogy means taking up another thing in order to make this one plain. > > —— *Mozi*, "Xiao Qu" (Warring States period; translated here by the author) In the 16 November 2026 episode of Medsider, host Scott Nelson interviews Lorne Lucree, founder and CEO of Wizard Wellness, about selling a drug-free three-step allergy care system on an aisle nobody had touched. Lucree's approach was to carry over, wholesale, the vocabulary consumers had already bought into in skincare and gut health — resveratrol, probiotics, a three-step routine — and so avoid paying to educate the category from scratch. He says a 600-person study run before launch found that three out of four allergy sufferers use three to five products at once, which is why the brand is structured as a routine instead of a single silver bullet. The claim holds only if something catches the borrowed trust: they ran a 28-day clinical and saw the nasal microbiome shift in people whose microbiome started out in dysbiosis. Worth noting that the brand only began selling direct in February 2026 and reached physical shelves in August, and the episode contains no sales or repeat-purchase figures. ![Three of the four patient figures are marked, and on the right a crossed-out single cure-all bottle sits opposite a lit-up three-step routine.](/figures/four-patients-three-stack-en.svg) ## The move itself: trust can be borrowed from another aisle Lucree's starting point was his own problem. He spent more than twenty years in beauty and personal care — global marketing at L'Oréal, product development at Clinique under Estée Lauder, then five years as chief innovation officer at Voyant Beauty, the largest beauty and personal care contract manufacturer in North America, running a team of eighty-five chemists and technicians, and after that advising Unilever's prestige portfolio on innovation. He has also been an allergy sufferer, worse with age. Three years ago he flew to Spain to see family, forgot his nasal spray, and ended up at a pharmacy trying to pronounce the active ingredient's chemical name. The pharmacist politely steered him to another section and handed him something that was neither prescription nor OTC: hyaluronic acid, botanicals, vitamin C, amino acids. He had been looking at those ingredients in skincare for two decades. What went through his head, he says, was "I never thought you could use these in nasal care," followed by "is the mode of action the same?" That curiosity became Wizard Wellness. Building the product and getting people to believe in it are two different jobs. He says that in the early days, when he pitched the company to investors, the first question was always the same one: is the science real? Microbiome had been worn out as a word, and people braced themselves on hearing it. So he skipped the teaching. He picked ingredients consumers would recognise: resveratrol comes from skincare, people know it comes from red wine and signals antioxidants, and he says it does the same work in your nose. Probiotics are a concept consumers learned from sodas like Poppi, and he says that logic travels too. The structure borrows as well — the line is laid out as a skincare routine, cleanse, relieve, balance. His reasoning is that nobody treats a cleanser alone as a finished skincare regimen; people are used to a sequence, and used to the brand telling them how to walk through it. No allergy brand does that, so shoppers standing in front of that shelf have to assemble a regimen themselves. ![On the left, a skincare and gut-health shelf is packed with bottles and carries three already-recognized labels, and a thick arrow moves those labels as a batch to the empty allergy shelf on the right, where a shopper stands in front of bare racks.](/figures/borrow-trust-from-another-shelf-en.svg) ## The evidence: they can't say what probiotics do, but they know it means good The sharpest piece of evidence comes from the concept testing they ran before launch. The product concept mentioned probiotics, and Lucree says testers reacted strongly enough to surprise him. His reading: they could not say what probiotics actually do, yet they knew the word stood for something good. It looked good, and that was enough. That line lays the mechanism bare. What gets borrowed is a positive label another category already paid to establish, and the knowledge stays behind. So the shelf message is compressed into three layers in order: first, there is a steroid-free, drug-free alternative and it works; second, it gives you relief right away; third, it preserves and strengthens the nasal microbiome. The third layer is the science itself, and it sits last — homework for after the purchase, once a customer is inside the brand's world. ![A three-step stack runs from wide to narrow, the first two steps are seen before the purchase, and the narrowest step, the science itself, falls below the dotted line that marks after the purchase.](/figures/shelf-message-three-layers-en.svg) Two things catch that label. One is the 28-day clinical, designed with a microbiome research partner he had known since his Unilever days, looking at the link between a strengthened nasal microbiome and quality of life: people in dysbiosis showed a shift at 28 days, alongside self-reported relief, better sleep, looking less worn out. Lucree says the largest improvement showed up in those who had rated their own symptoms worst. The dual modulation through nasal and gut delivery is what their patent covers. He gives no sample size or effect size. The second sits closer to the shelf. Every product also gets its own consumer panel — twenty-five, fifty or a hundred people — measured at immediate, day three and day seven, and the percentages get printed on the pack. They call it proof in the potion. His reasoning is that the data from beauty taught him consumers trust that kind of percentage more than an abstract clinical number, because they are already reading ratings and reviews: what they want to know is how it went for people like them. ![An axis of distance from the shelf puts the 28-day clinical study at the far end where only willing readers see it, while the panel-test percentages printed on the pack sit right in front of the shopper.](/figures/two-kinds-of-proof-distance-en.svg) ## Where the move breaks Lucree names the first crack himself: microbiome has been washed to death as a term. Borrow a word that another aisle has overused and you borrow the fatigue along with it — the investor's opening question about whether the science is real is that fatigue talking back. His answer is to put the clinical and the consumer testing up front, which only works on people willing to read. The person standing in front of a Walmart shelf will not read. The second crack is felt experience. A borrowed label buys the first purchase; after that the product has to hold people on its own, and the trouble with the natural route is that results are slow to show. Lucree says American consumers were spoiled by Tylenol — take a pill, feel something within half an hour. So they followed what supplement brands do and wrote out, on the science page, what you see by day three, day seven, day fourteen, day twenty-eight, with the email flow knocking at each of those points to tell you what this day should feel like. Expectation management became part of the product. ![Two curves of felt effect, the drug one rising steeply to its peak within half an hour and the natural one climbing slowly along day 3, day 7, day 14 and day 28, with an email marked at each climbing point.](/figures/expectation-curve-days-en.svg) The third crack is time. Zyrtec has launched its first drug-free product, and it is being merchandised next to Wizard in those same retailers. Lucree says he expects more players, which is why he wants to claim that spot on the shelf early. Anyone can borrow an analogy; arriving first only means starting the education earlier. ## Why it may be retail access or the supply chain doing the work The episode frames the speed of the rollout as a storytelling win, and while listening I kept turning over three other explanations. The first is retail relationships. Lucree's method is to get retailers "in the kitchen" as early as possible — the minute Walmart gave a green light he packed his bags for Bentonville, and he pushed brokers for Target meetings before anything had been signed. He says retailers do not define the brand, yet they know their own shopper better than anyone, and that knowledge comes free. He is also blunt about one thing: an investor made his introductions to Walmart and CVS, and without that connection none of it happens. A brand reaching 1,400 CVS stores, 1,700 Walmart stores and 1,000 Target stores within nine months of launch owes a great deal to that line. The second is the supply chain barrier. He has been a contract manufacturer's innovation chief, and he says building a supply chain for an allergy brand was one of the hardest things he has done: finding someone to fill that packaging, redesigning the packaging itself (they hold two design patents on it, plus some medical device work), running tox testing on the ingredients. His judgement is that the barrier makes the category hard to replicate. Which also means part of his lead comes from others being unable to get in, and has nothing to do with storytelling. The third is friction. He cites a comparison he calls cheesy himself — the Steve Jobs move of pulling friction out wherever you find it. Allergy care is full of friction: it stings, you cannot use it for more than three days, mixing distilled water for a rinse is a chore. So the rinses come pre-mixed and preserved, the oral dose is a fast-dissolve strip that tastes good instead of a pill that makes people gag, and the packaging looks like something you would leave out on a shelf. Those changes raise retention on their own, whether or not the shopper understands anything about a microbiome. So how do you tell the explanations apart? The episode cannot settle it, because the data is too young: direct sales started in February 2026, physical distribution landed across August and early September, and there are no sales, repeat-purchase or sell-through numbers in the conversation. The test sits in the future — that Zyrtec product is on the shelf right beside them, so if storytelling is the main engine, Wizard should hold its share once both of them are borrowing the same analogy; if the moat is retail access and the supply chain, whatever holds Zyrtec off will be something else. ![Four lines of differing thickness converge from the left on the same outcome of nine months on shelf, with a question mark to the right of that outcome and the point that could tell them apart noted below.](/figures/four-explanations-one-outcome-en.svg) ## A few other things worth keeping - Timing his raises against his milestones is the mistake he names as one of his bigger ones. The brand has raised close to seven million dollars, starting with a pre-seed of about a million and a half in October 2024. He says every time he needed capital he was a month or two short of a written retail commitment, and that piece of paper would have supported the valuation. - "Not all money is the same" gets concrete in his telling: whether an investor leans in, whether they can make an introduction, whether they will sanity-check you when your head is not clear. He adds a stage problem — he went too big at the outset, and the people who live at your stage are the ones who understand what you are going through. - The chemists are the magic makers. Running an eighty-five person team at a contract manufacturer, his observation was that chemists are often the last to know what the company is doing and sit lowest on the totem pole, while the formulation is what gives a brand longevity. His method is to pull them into the big picture and find the language that reaches them, translating emotions into numbers. - His rapid-fire lesson was "don't be hard on yourself," with a rider: that swing can happen inside twenty-four hours. ![On a timeline, each funding arrow lands one or two months before a valuation step, and the steps only rise after a retailer puts its commitment in writing.](/figures/funding-ahead-of-milestone-en.svg) ## Where to look yourself - Medsider, episode released 16 November 2026, Scott Nelson interviewing Wizard Wellness founder Lorne Lucree: https://medsider.com/ - The science page on Wizard Wellness's own site, which Lucree says they rewrote many times over: https://wizardwellness.com/ - For the link between nasal microbiome dysbiosis and allergic rhinitis, search PubMed for review articles on that phrase - Product pages from a few supplement brands, to see how "what you see by day N" gets used as a reason to buy ## The One Thing to Take Away If you want someone with no background to believe something new, the cheap route is to find another thing they have already bought into and carry that label across. They do not need to understand it. They only need to recognise it. Here is something I have tried myself. Pick something you have been wanting to talk someone around to — switching insurance, getting a parent to go for a check-up, moving a colleague onto a different process. Hold off on writing your reasons. First list, on paper, three things that person has spent money or time on in the past year, then pick one of the three as your entry point and say your piece in the language of that thing. Then watch where their reaction lands: if they ask you for details, you picked the right door; if they come back asking what the thing even is, you are still teaching from scratch. ![Three things he has paid for in the past year converge on one entrance, that entrance leads to the thing you want to say, and the exit forks into asking for details or asking what that even is.](/figures/pick-an-entrance-he-already-paid-for-en.svg)